The US Court of Appeals for the First Circuit held that pharmaceutical companies that wrongly list patents in FDA’s Orange Book must prove they acted in good faith to avoid antitrust liability. In re Lantus Direct Purchaser...more
3/6/2020
/ Antitrust Litigation ,
Antitrust Provisions ,
Antitrust Violations ,
Corporate Counsel ,
Food and Drug Administration (FDA) ,
Orange Book ,
Patents ,
Pharmaceutical Industry ,
Pharmaceutical Patents ,
Sanofi-Aventis ,
Sherman Act
December 19th, 2019, the Environmental Protection Agency (EPA) announced its approval of 10 new pesticides for use on hemp products. EPA’s approval of nine biopesticides and one conventional pesticide provides greater...more
12/23/2019
/ Agricultural Sector ,
Cannabidiol (CBD) oil ,
Cannabis Products ,
Cannabis-Related Businesses (CRBs) ,
Comment Period ,
Decriminalization of Marijuana ,
Department of Agriculture ,
Environmental Protection Agency (EPA) ,
Food and Drug Administration (FDA) ,
GRAS ,
Hemp ,
Hemp Cultivation ,
Hemp Related Businesses ,
Interim Final Rules (IFR) ,
Marijuana ,
Marijuana Related Businesses ,
Pesticides ,
Proposed Rules ,
Public Comment ,
Regulatory Authority ,
USDA
On Friday May 31, 2019, the Food and Drug Administration (FDA) held a public hearing on the topic of cannabis or cannabis-derived compounds. The FDA held the hearing to gather information regarding the safety risks and health...more
6/7/2019
/ Cannabidiol (CBD) oil ,
Cannabis Products ,
Controlled Substances Act ,
Decriminalization of Marijuana ,
Dietary Supplements ,
Federal Food Drug and Cosmetic Act (FFDCA) ,
Food and Drug Administration (FDA) ,
GRAS ,
Health and Safety ,
Hemp ,
Labeling ,
Marijuana ,
Marijuana Related Businesses ,
Public Comment ,
Public Hearing